However, all CETP inhibitors, including the novel CETP-inhibitor obicetrapib, increase plasma concentrations of apolipoprotein-E (Apo-E) [4], which is associated with decreased risk of dementia, in particular for Alzheimer’s disease (AD). The gene discussed is APOE; the disease is early-onset autosomal dominant Alzheimer disease.